Ribupatide
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 140
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Group 1: HRS9531 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Group 2: HRS9531placebo | Obesity or overweight | n/r | n/r | n/r | n/r |